NASDAQ OMX

European Consumers Embrace Elixinol Hemp Oil CBD as Part of Wellness Movement

Dela

Elixinol Brand Cannabidiol Hemp Oil Now Available Throughout Europe

DENVER, July 19, 2017 (GLOBE NEWSWIRE) -- Already regarded as one of the fastest growing and most trusted cannabidiol brands in the world, Elixinol announces expansion into Europe.

Photos accompanying this announcement are available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/9918871c-5c3d-4974-8039-2c687211b538

http://www.globenewswire.com/NewsRoom/AttachmentNg/187d5574-95f9-40d9-8e22-061d660fd2a6

http://www.globenewswire.com/NewsRoom/AttachmentNg/0978ad48-d660-4b86-b161-e457289c8402

http://www.globenewswire.com/NewsRoom/AttachmentNg/21045979-c22e-488c-8084-fdaaefb284a4

Seven Elixinol hemp oil CBD products will be available to consumers throughout Europe including best-sellers such as Liposomes, noted for their great taste and increased bioavailability, the targeted topical Rescue Balm, and CBD capsules.

Consumers throughout the world use Elixinol's CBD hemp oil for both lifestyle improvement and condition treatment. Elixinol expects Europeans will embrace CBD hemp oil products as part of an overall wellness regimen.

"Faced with shrinking healthcare budgets and an increased emphasis on well-being, European consumers are looking for ways to get better rest, reduce stress and optimize their fitness efforts," said Husong.

With increasing numbers of consumers in Europe embracing fitness, organic foods and stress reduction, Elixinol's market entry meets the needs of the growing marketplace.

According to Statista, over 52% of Western Europeans rated their own health knowledge as sufficient or excellent, "translating into greater understanding of health measures and what individuals should do to improve their own health." The health and wellness market value in Western Europe is already over 145 million euros with more growth projected. Western Europe's dietary supplement market is projected to reach over 5.6 million euros by 2020. 

"From executives who crave increased focus and stress reduction to fitness aficionados seeking faster recovery, since we launched, sales in Europe have exceeded our aggressive expectations," said Chris Husong, Director of Global Marketing and Sales for Elixinol.

"Hemp and its benefits are nothing new for Europeans," said Marco Cappiello, Director of European Operations for Elixinol. "But with concerns over serving size, potency and purity now addressed by Elixinol's rigorous and transparent testing process, Europeans can now purchase CBD hemp oil with confidence," he continued.

To eliminate consumer concerns about metals, solvents, pesticides as well as potency and purity, Elixinol is the only global brand to post independent laboratory test results online and follows a strict pharmaceutical-grade testing process.

Elixinol will source its European CBD from existing relationships with Northern European organic farmers who have been cultivating hemp for generations.

"It's as if we're coming home," said Husong. "We've had relationships in Europe since our inception, being able to deliver the end product to the European consumer is incredibly satisfying."

Elixinol products are available to customers in Europe on elixinol.com and in various retail health outlets throughout Spain and Italy.

About Elixinol: 
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products in 22 countries globally including United States, Japan, Puerto Rico, Brazil and throughout Europe. More information available at Elixinol.com.

Photos may also be available via AP PhotoExpress.

Media Contact: 
Chris Husong
Elixinol
+1 844-804-3504 ext 420
chris@elixinol.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elixinol via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Tier1CRM Receives Significant Equity Capital to Accelerate Growth11.12.2017 23:28Pressmeddelande

Raises $34 Million (USD) from Leading Financial and Strategic Investors to Continue Building on Recent Successes TORONTO and NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Tier1CRM (Tier1), a provider of cloud-based customer relationship management (CRM) solutions for the capital markets industry, announced today that it raised $34 million (USD) in growth equity financing from a group of investors led by Wavecrest Growth Partners, with participation from MassMutual Ventures and Salesforce Ventures. Founded in 2008 by Mark Notten and Phil Dias and based in Toronto, Tier1 is a leading provider of CRM and customer engagement SaaS solutions to sell-side and buy-side financial services clients spanning sales and trading desks, investment banks and investment managers. Major global financial institutions leverage the Tier1 platform to efficiently and more profitably manage client relationships, improve internal transparency and collaboration, manag

Minerva Neurosciences Names Richard Russell President11.12.2017 22:40Pressmeddelande

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell as President.  Dr. Remy Luthringer will continue as Chief Executive Officer of Minerva while resigning his position as President. Mr. Russell has more than 20 years of experience leading commercial operations, including developing and implementing sales and marketing activities for major biotechnology and pharmaceutical brands in North America and the European Union.  His experience encompasses several therapeutic areas, including CNS disorders, neurodegenerative disorders, cardiovascular disease and women's health. "We welcome Rick Russell to Minerva, where his wide-ranging commercial expertise will help ensure the effective transition from late-stage clinical development to the market for our product c

Sonoco-Alcore to Increase Paperboard Prices in Europe11.12.2017 22:30Pressmeddelande

BRUSSELS, Belgium, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sonoco-Alcore S.a.r.l. today announced it will again raise prices by a further €50 per tonne on all recycled paperboard grades sold in the Company's Central European regions. The price change is effective with shipments on or after the 1st January 2018. "The continued strong demand for core board across Europe, along with expectations that already elevated raw material and energy prices will continue to rise into the New Year, leave us little choice but to implement this increase," said Phil Woolley, Director - Paper Europe. Sonoco-Alcore S.a.r.l. is wholly-owned by Sonoco (NYSE:SON) and operates 29 tubes and cores plants and four paperboard mills in Europe. Contact: Roger Schrum +843/339-6018 roger.schrum@sonoco.com     This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corpor

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors11.12.2017 14:15Pressmeddelande

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of William F. Doyle and Hans Peter Hasler to the Board of Directors of the Company. "Bill Doyle and Hans Peter Hasler bring distinguished leadership backgrounds and complementary sets of expertise to Minerva's Board of Directors," said Dr. Fouzia Laghrissi-Thode, Board member and chairperson of the search committee at Minerva.  "Their bio-pharma industry-specific experience, which encompasses strategic development, partnering, licensing, product launches, marketing and commercialization, will benefit Minerva as the foundation is laid for the commercialization of the Company's products currently in advanced clinical development.  We look forward to Bill's and Hans's entrepreneurial and operational perspectives on how Minerva can b

Sabina Gold & Silver Announces Commencement of the Review of its Water License Applications for the Back River Project11.12.2017 13:30Pressmeddelande

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sabina Gold & Silver Corp (TSX:SBB.T), ("Sabina" or the "Company") is pleased to announce that the Nunavut Water Board (NWB) has commenced public review of the Type A and Type B water license applications related to initial development, mine construction and operation of the Back River Project (the "Project" or "Back River"). As announced on December 6, 2017, the Minister of Indigenous and Northern Affairs Canada, on behalf of the five responsible federal Ministers, accepted Nunavut Impact Review Board's recommendation for the Project to proceed to the regulatory and licensing phase.  The NIRB has advised that the final Project Certificate will be issued on or before January 4, 2018. The Type B water license would enable Sabina to commence certain initial pre-development activities in 2018 including onsite construction of service roads and laydown pads, and the mobilization of fuel, supplies and equipment at t

Standard Lithium Provides Development Update on California Lithium Project11.12.2017 11:00Pressmeddelande

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to provide an update on the development work taking place at the Company's California Lithium Project; comprising the Bristol Dry Lake and the Cadiz Dry Lake lithium brine properties located in the Mojave Desert, California. A total of six new separate evaporation ponds have been installed on the Bristol Dry Lake Property to further assess the role that short-duration passive solar evaporation may play in processing the lithium brines encountered at the project.  Previous work demonstrated that, owing to extremely high evaporation rates in the project area, it is possible to concentrate brines from initial lithium concentrations of 146 mg/L to concentrations of 686 mg/L in approximately 7 weeks (note, this average lithium concentration was previously reported as 556 mg/L in news release dated 10th Oct 2017,

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum